Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
A phase 2 trial of Trastuzumab rezetecan in biliary tract cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT06413745 by Jiangsu HengRui Medicine Co., Ltd., with 59 participants enrolled, started 2024-06-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: SHR-A1811.
Similar pages
not linked directly; found by shared links- TrialA Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Shares Jiangsu Hengrui Pharmaceuticals, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialSafety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.